ID   IMR-5
AC   CVCL_1306
SY   IMR 5; IMR5; IMR-05; Institute for Medical Research-5
DR   BTO; BTO:0005846
DR   CLO; CLO_0006950
DR   CLDB; cl5097
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-3610
DR   cancercelllines; CVCL_1306
DR   Cell_Model_Passport; SIDM01206
DR   ChEMBL-Cells; CHEMBL3308201
DR   ChEMBL-Targets; CHEMBL2366209
DR   Cosmic; 907170
DR   Cosmic; 1019939
DR   Cosmic; 1109364
DR   Cosmic; 1161989
DR   Cosmic; 1167417
DR   Cosmic; 1890113
DR   Cosmic-CLP; 907170
DR   DepMap; ACH-002248
DR   EGA; EGAS00001000978
DR   GDSC; 907170
DR   GEO; GSM1669935
DR   GEO; GSM2371236
DR   GEO; GSM2394389
DR   IARC_TP53; 21396
DR   ICLC; HTL00009
DR   LINCS_LDP; LCL-1984
DR   PharmacoDB; IMR5_660_2019
DR   PRIDE; PXD030304
DR   PubChem_Cell_line; CVCL_1306
DR   Wikidata; Q54897648
RX   PubMed=6160155;
RX   PubMed=12536080;
RX   PubMed=15150091;
RX   PubMed=16822308;
RX   PubMed=18724359;
RX   PubMed=20164919;
RX   PubMed=23202128;
RX   PubMed=24466371;
RX   PubMed=27397505;
RX   PubMed=28350380;
RX   PubMed=30894373;
RX   PubMed=31581737;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Caucasian.
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0%; Native American=0.86%; East Asian, North=0%; East Asian, South=0.06%; South Asian=4.46%; European, North=75.37%; European, South=19.24% (PubMed=30894373).
CC   Derived from site: Metastatic; Abdomen; UBERON=UBERON_0000916.
ST   Source(s): Cosmic-CLP; PubMed=31581737
ST   Amelogenin: X,Y
ST   CSF1PO: 11,12
ST   D13S317: 9
ST   D16S539: 8
ST   D18S51: 12,15
ST   D19S433: 14,15
ST   D21S11: 30,31
ST   D2S1338: 23,24
ST   D3S1358: 16
ST   D5S818: 11,12
ST   D7S820: 9,10
ST   D8S1179: 13
ST   FGA: 21,24
ST   Penta D: 11,12
ST   Penta E: 7,15
ST   TH01: 7,9.3
ST   TPOX: 11
ST   vWA: 15
DI   NCIt; C3270; Neuroblastoma
DI   ORDO; Orphanet_635; Neuroblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0346 ! IMR-32
SX   Male
AG   1Y1M
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 33
//
RX   PubMed=6160155; DOI=10.1016/S0021-9258(19)70222-1;
RA   Momoi M., Kennett R.H., Glick M.C.;
RT   "A membrane glycoprotein from human neuroblastoma cells isolated with
RT   the use of a monoclonal antibody.";
RL   J. Biol. Chem. 255:11914-11921(1980).
//
RX   PubMed=12536080; DOI=10.1016/S0304-3835(02)00581-5;
RA   Fischer M., Berthold F.;
RT   "Characterization of the gene expression profile of neuroblastoma cell
RT   line IMR-5 using serial analysis of gene expression.";
RL   Cancer Lett. 190:79-87(2003).
//
RX   PubMed=15150091; DOI=10.1158/0008-5472.CAN-03-0809;
RA   Schaefer K.-L., Brachwitz K., Wai D.H., Braun Y., Diallo R.,
RA   Korsching E., Eisenacher M., Voss R., van Valen F., Baer C., Selle B.,
RA   Spahn L., Liao S.-K., Lee K.A.W., Hogendoorn P.C.W., Reifenberger G.,
RA   Gabbert H.E., Poremba C.;
RT   "Expression profiling of t(12;22) positive clear cell sarcoma of soft
RT   tissue cell lines reveals characteristic up-regulation of potential
RT   new marker genes including ERBB3.";
RL   Cancer Res. 64:3395-3405(2004).
//
RX   PubMed=16822308; DOI=10.1186/1471-2407-6-177;
RA   Dam V., Morgan B.T., Mazanek P., Hogarty M.D.;
RT   "Mutations in PIK3CA are infrequent in neuroblastoma.";
RL   BMC Cancer 6:177.1-177.10(2006).
//
RX   PubMed=18724359; DOI=10.1038/nature07261;
RA   Mosse Y.P., Laudenslager M., Longo L., Cole K.A., Wood A.,
RA   Attiyeh E.F., Laquaglia M.J., Sennett R., Lynch J.E., Perri P.,
RA   Laureys G., Speleman F., Kim C., Hou C.-P., Hakonarson H., Torkamani A.,
RA   Schork N.J., Brodeur G.M., Tonini G.P., Rappaport E., Devoto M.,
RA   Maris J.M.;
RT   "Identification of ALK as a major familial neuroblastoma
RT   predisposition gene.";
RL   Nature 455:930-935(2008).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=23202128; DOI=10.1038/ng.2493;
RA   Sausen M., Leary R.J., Jones S., Wu J., Reynolds C.P., Liu X.-Y.,
RA   Blackford A.L., Parmigiani G., Diaz L.A. Jr., Papadopoulos N.,
RA   Vogelstein B., Kinzler K.W., Velculescu V.E., Hogarty M.D.;
RT   "Integrated genomic analyses identify ARID1A and ARID1B alterations in
RT   the childhood cancer neuroblastoma.";
RL   Nat. Genet. 45:12-17(2013).
//
RX   PubMed=24466371; DOI=10.1593/tlo.13544;
RA   Loschmann N., Michaelis M., Rothweiler F., Zehner R., Cinatl J.,
RA   Voges Y., Sharifi M., Riecken K., Meyer J., von Deimling A.,
RA   Fichtner I., Ghafourian T., Westermann F., Cinatl J. Jr.;
RT   "Testing of SNS-032 in a panel of human neuroblastoma cell lines with
RT   acquired resistance to a broad range of drugs.";
RL   Transl. Oncol. 6:685-696(2013).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=28350380; DOI=10.1038/sdata.2017.33;
RA   Harenza J.L., Diamond M.A., Adams R.N., Song M.M., Davidson H.L.,
RA   Hart L.S., Dent M.H., Fortina P., Reynolds C.P., Maris J.M.;
RT   "Transcriptomic profiling of 39 commonly-used neuroblastoma cell
RT   lines.";
RL   Sci. Data 4:170033-170033(2017).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31581737; DOI=10.3390/cells8101194;
RA   Povey J.F., Saintas E., Aderemi A.V., Rothweiler F., Zehner R.,
RA   Dirks W.G., Cinatl J. Jr., Racher A.J., Wass M.N., Smales C.M.,
RA   Michaelis M.;
RT   "Intact-cell MALDI-ToF mass spectrometry for the authentication of
RT   drug-adapted cancer cell lines.";
RL   Cells 8:1194.1-1194.12(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//